A Phase I, Open-label, Multicenter, Dose-Escalating Study to Evaluate the Safety and Tolerability of KH658 Gene Therapy in Participants with Neovascular Age-related Macular Degeneration
PHASE1Not yet recruitingINTERVENTIONAL
Enrollment
9
Participants
Timeline
Start Date
Not specified
Conditions
Age-Related Macular Degeneration
Interventions
DRUG
KH658
KH658: AAV vector containing a coding sequence for an anti-VEGF protein
All Listed Sponsors
lead
Chengdu Origen Biotechnology Co., Ltd.
INDUSTRY
NCT06825858 - A Phase I, Open-label, Multicenter, Dose-Escalating Study to Evaluate the Safety and Tolerability of KH658 Gene Therapy in Participants with Neovascular Age-related Macular Degeneration | Biotech Hunter | Biotech Hunter